Physician profile
Ann Robinson
NPI 1972957546
$1,674.33
in general payments reported to CMS, 2019-2025
13 companies · $938 in 2025
The $938 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $141 · 2023: $86.00 · 2024: $509 · 2025: $938.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,533.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $948.57 | 2024-2025 | Tremfya, Stelara |
| Abbvie INC. | $254.14 | 2022-2025 | |
| Lilly USA, LLC | $93.79 | 2025 | Omvoh |
| Pfizer INC. | $90.09 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $73.59 | 2023-2025 | Entyvio |
| Madrigal Pharmaceuticals | $58.94 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $31.77 | 2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $27.88 | 2023 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.86 | 2025 | Xifaxan |
| Ferring Pharmaceuticals INC. | $23.74 | 2023 | Rebyota |
| Celltrion USA INC. | $18.69 | 2025 | Vegzelma |
| Celgene Corporation | $16.17 | 2024 | Zeposia |
| Exact Sciences Corporation | $13.10 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.